INTERNATIONAL AWARDS FOR RESEARCH IN LEUKAEMIA LADY TATA MEMORIAL TRUST

The Trustees of the Lady Tata Memorial Trust invite applications for Awards for personal support for research on leukaemia and related conditions, in the Academic Year beginning 1st October 2022. Awards are restricted to studies of the treatment, epidemiology, pathogenesis, immunology and genetic basis of leukaemia and related haematological malignant disorders such as

lymphoma and multiple myeloma. Applications not related to the field of leukaemia or closely related disorders will not be considered.

Awards are open to suitably qualified investigators of any nationality. Successful applicants are likely to have completed a PhD no more than 6 years prior to the application deadline. Priority will be given to those intending to move to other centres, with a view to establishing scientific collaboration between laboratories and/or progress toward scientific independency. Awards are tenable for one year only; applicants are expected to seek funding from other sources for continuation of their work beyond the first year. Awards in recent years have been between £25,000 and £35,000 per annum.

In addition, one Lady Tata Studentship for a student entering an MPhil/PhD programme is available. The MPhil/PhD studentship will normally be granted for two years in the first instance. Renewal for a third year will only be considered for these studentships on the strength of a further application in the second year of their studies.

To apply please visit our website: www.ladytatatrust.tatatrusts.org. Any enquiries should be addressed to Sonia Woodward at sonia@tata.co.uk.

Application open date is 1st January 2022. Deadline for applications is 15th March 2022. Awards will be announced by the Trustees in June 2022.

Please apply via recruiter’s website.

Check Also

2022 SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship

Cette bourse clinique soutient un diplôme en médecine ou un diplôme combiné MD / PhD et a un intérêt direct à faire avancer la recherche et la traduction d'approches immunothérapeutiques pour le traitement des patients atteints d'un cancer du poumon.

Leave a Reply

Your email address will not be published. Required fields are marked *